Telomerase-negative tumor cells maintain their telomeres via an alternative lengthening of telomeres (ALT) mechanism.This process involves the association of telomeres with promyelocytic leukemia nuclear bodies (PML-NBs). Here, the mobility of both telomeres and PML-NBs as well as their interactions were studied in human U2OS osteosarcoma cells, in which the ALT pathway is active. A U2OS cell line was constructed that had lac operator repeats stably integrated adjacent to the telomeres of chromosomes 6q, 11p, and 12q. By fluorescence microscopy of autofluorescent LacI repressor bound to the lacO arrays the telomere mobility during interphase was traced and correlated with the telomere repeat length. A confined diffusion model was derived that describes telomere dynamics in the nucleus on the time scale from seconds to hours. Two telomere groups were identified that differed with respect to the nuclear space accessible to them. Furthermore, translocations of PML-NBs relative to telomeres and their complexes with telomeres were evaluated. Based on these studies, a model is proposed in which the shortening of telomeres results in an increased mobility that could facilitate the formation of complexes between telomeres and PML-NBs.
INTRODUCTIONTelomeres are specialized chromatin structures at the end of linear chromosomes, in which repetitive DNA sequences (5Ј-TTAGGG-3Ј in vertebrates) associate into a nucleoprotein complex (de Lange et al., 2006). This complex-the "telosome"-protects the chromosome ends from degradation and genomic rearrangement and includes the "shelterin" proteins TRF1, TRF2, and POT1 that directly recognize the TTAGGG repeat sequence (de Lange, 2005;Bertuch and Lundblad, 2006;Croy and Wuttke, 2006;Blasco, 2007). Because of incomplete DNA synthesis at the chromosome ends, 50 -200 base pairs of telomeric DNA are lost during each replication cycle (Harley et al., 1990;Martens et al., 2000). After ϳ60 -80 cell divisions telomere repeats are shortened from a typical initial length of 10 -15 kb in human cells to ϳ5 kb and below, which triggers cell senescence or apoptosis (Harley et al., 1990;Martens et al., 2000;Blasco, 2007). Accordingly, tumor cells need to compensate the loss of their telomere repeats in order to sustain an unlimited proliferative potential. In most cases this is accomplished by reactivating telomerase, a reverse transcriptase that synthesizes telomeric repeats at the chromosome ends (Greider and Blackburn, 1985;Chan and Blackburn, 2004;Collado et al., 2007;Johnson and Broccoli, 2007). However, a fraction of ϳ10 -15% of tumors is able to maintain their telomeres in the absence of telomerase activity. This process has been designated as alternative lengthening of telomeres (ALT; Bryan et al., 1995;Neumann and Reddel, 2006;Johnson and Broccoli, 2007). In yeast and mammals, it has been shown that the ALT mechanism involves homologous recombination events between telomere repeats (Dunham et al., 2000;Kass-Eisler and Greider, 2000;Lundblad, 2002;Muntoni and Reddel, 2005). It is characte...